Straits Times Index
3,316.63 +8.73 (+0.26%) Nikkei
39,071.18 +454.08 (+1.18%) Hang Seng
18,930.02 -265.58 (-1.38%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,462.00 -277.93 (-0.40%) CMC Crypto 200
1,511.30 -15.11 (-0.99%)
PreveCeutical Medical Inc. (18H.F)
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0035 x 0 |
| Ask | 0.0280 x 0 |
| Day's range | 0.0100 - 0.0100 |
| 52-week range | 0.0100 - 0.0275 |
| Volume | |
| Avg. volume | 4,472 |
| Market cap | 7.236M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
CNW GroupPREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM
PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy program using our developed and in vitro validated Smart-siRNA sequences, which when paired with our proprietary bioresponsive lipid-nanoparticulate delivery systems (US patent no. 11,566,044) effectively target the PTPN1 gene.
CNW GroupPreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application
PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is proud to announce that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this technology. The company's commitment to advancing medical research is demonstrated through its comprehensive resea
CNW GroupPreveCeutical Showcases Dynamic Evolution in AI Strategy
PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), PreveCeutical Medical Inc. marks today as an important chapter in the journey of PreveCeutical Medical Inc., a pioneering figure in the realm of medical technology. The Company unveils a comprehensive narrative around its growing involvement and innovation in the vast domain of Artificial Intelligence (AI).
